Page 92 - Case Lab Case Analysis
P. 92
Do Nothing
Phissons are in a position of strength they have invested £250 million
and are weeks away from the launch of proxydychromil which has
received approval in both the UK and US for sale.
Furthermore it is a drug that treats both primary forms of asthma.
Strengths Weaknesses
- Major co. in industry - Command and control structure
- Financial strength
- Effective barriers to entry
Opportunities Threats
- global markets - Ethics policy or lack of one
- developed country approval
- global expansion
